Sai Life Sciences Ltd (SAILIFE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039479,
    "name": "Sai Life",
    "stock_name": "Sai Life",
    "full_name": "Sai Life Sciences Ltd",
    "name_url": "stocks-analysis/sai-life",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "878.70",
    "chg": 39.05,
    "chgp": "4.65%",
    "dir": 1,
    "prev_price": "839.65",
    "mcapval": "18,267.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 544306,
    "symbol": "SAILIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE570L01029",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "3.54 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/sai-life-10039479-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sai Life's Evaluation Metrics Revised Amidst Positive Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sai-life-upgraded-from-sell-to-hold-by-marketsmojo-on-19-jun-2025-3733001",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SaiLife_mojoScore_3733001.png",
        "date": "2025-11-27 10:06:45",
        "description": "Sai Life, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a revision in its evaluation metrics reflecting shifts in its financial and market performance. This adjustment highlights evolving perspectives on the company’s quality, valuation, financial trends, and technical outlook amid a backdrop of steady operational growth and market activity."
      },
      {
        "title": "Are Sai Life latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-sai-life-latest-results-good-or-bad-3712706",
        "imagepath": "",
        "date": "2025-11-18 19:32:50",
        "description": "Sai Life Sciences has reported its Q2 FY26 results, showcasing notable operational performance. The company achieved a net profit of ₹83.84 crores, reflecting a significant year-on-year increase of 101.98%. Revenue for the quarter reached ₹537.47 crores, marking a 35.88% growth compared to the same period last year, and an 8.27% sequential improvement from the previous quarter. This growth trajectory suggests a recovery in client demand and effective project execution.\n\nThe operating margin improved to 27.13%, up from 25.84% a year earlier, indicating enhanced operational leverage. The PAT margin also saw an increase, rising to 15.60%, which is a 511 basis point improvement year-on-year. The company’s operating profit, excluding other income, was reported at ₹145.83 crores, reflecting a 42.67% increase from the previous year.\n\nInterest expenses have significantly decreased by 55.32% year-on-year to ₹9.35 cr..."
      },
      {
        "title": "How has been the historical performance of Sai Life?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-sai-life-3709309",
        "imagepath": "",
        "date": "2025-11-17 23:27:40",
        "description": "Answer:\nThe historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025.\n\nBreakdown:\nSai Life's consolidated net sales increased from 1,465.18 Cr in March 2024 to 1,694.57 Cr in March 2025, reflecting a strong upward trend in total operating income as well. The company's total expenditure rose to 1,288.91 Cr from 1,179.69 Cr, with notable increases in raw material costs and employee costs. Operating profit (PBDIT) improved significantly, reaching 442.44 Cr, up from 314.58 Cr, while profit before tax also saw a substantial rise to 227.70 Cr from 109.23 Cr. Consequently, profit after tax surged to 170.13 Cr compared to 82.81 Cr the previous year. The operating profit margin increased to 23.94% from 19.48%, and the PAT margin improved to 10.04% from 5.65%. On the balance sheet, total assets grew to 3,145.78 Cr from 2,262.00 Cr, driven by increases in s..."
      },
      {
        "title": "Sai Life Sciences Q2 FY26: Strong Profit Surge Masks Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/sai-life-sciences-q2-fy26-strong-profit-surge-masks-valuation-concerns-3709535",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SaiLifeSciences_quaterlyResult_3709535.png",
        "date": "2025-11-17 22:47:58",
        "description": "Sai Life Sciences Ltd., a contract research and manufacturing services (CRAMS) provider in the pharmaceutical sector, delivered a robust performance in Q2 FY26 with net profit surging 101.98% year-on-year to ₹83.84 crores, up 38.67% sequentially from ₹60.46 crores in Q1 FY26. The Hyderabad-based company, with a market capitalisation of ₹18,529 crores, demonstrated strong operational momentum as revenue climbed 35.88% YoY to ₹537.47 crores, though the stock's premium valuation at 107 times trailing earnings continues to raise eyebrows among value-conscious investors."
      },
      {
        "title": "Are Sai Life latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-sai-life-latest-results-good-or-bad-3680591",
        "imagepath": "",
        "date": "2025-11-07 19:27:44",
        "description": "Sai Life Sciences' latest financial results for Q2 FY26 present a mixed picture of performance. The company reported a net profit of ₹60.46 crores, reflecting a significant quarter-on-quarter decline of 31.51%. This drop in profitability occurred despite a strong year-on-year revenue growth of 77.47%, with net sales reaching ₹496.42 crores. However, sequentially, revenues fell by 14.34% from the previous quarter, indicating operational challenges that may be impacting the company's ability to maintain profitability alongside its growth trajectory.\n\nThe operating margin, excluding other income, contracted to 24.36%, down from 27.19% in the prior quarter, suggesting that cost pressures are outpacing revenue growth. The profit after tax margin also saw a decline, from 15.23% to 12.18%, highlighting the need for the company to address these margin pressures effectively.\n\nOn a positive note, the balance sheet re..."
      },
      {
        "title": "Sai Life Sciences Q2 FY26: Robust Revenue Growth Masks Margin Pressure and Profit Decline",
        "link": "https://www.marketsmojo.com/news/result-analysis/sai-life-sciences-q2-fy26-robust-revenue-growth-masks-margin-pressure-and-profit-decline-3679778",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SaiLifeSciences_quaterlyResult_3679778.png",
        "date": "2025-11-07 10:52:14",
        "description": "Sai Life Sciences Ltd., a contract research and manufacturing organisation (CRAM) in the pharmaceutical sector, reported mixed results for Q2 FY26, with net profit declining 31.51% quarter-on-quarter to ₹60.46 crores despite robust revenue growth. The stock reacted sharply, falling 4.30% to ₹882.45 on November 7, 2025, as investors digested the margin compression and sequential profit decline. With a market capitalisation of ₹18,546.61 crores, the small-cap pharma player finds itself navigating a challenging period of operational adjustments despite maintaining strong year-on-year growth momentum."
      },
      {
        "title": "How has been the historical performance of Sai Life?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-sai-life-3677433",
        "imagepath": "",
        "date": "2025-11-06 23:07:14",
        "description": "Answer:\nThe historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Sai Life reported net sales of 1,694.57 crore, an increase from 1,465.18 crore in the previous year. Total operating income also rose to 1,694.57 crore, with total expenditure excluding depreciation increasing to 1,288.91 crore from 1,179.69 crore. The operating profit (PBDIT) saw a substantial rise to 442.44 crore, compared to 314.58 crore in March 2024, leading to a profit before tax of 227.70 crore, up from 109.23 crore. Consequently, the profit after tax reached 170.13 crore, nearly doubling from 82.81 crore the previous year. The company's earnings per share (EPS) decreased to 8.16 from 45.88, while the operating profit margin improved to 23.94% from 19.48%. On the balance sheet, total assets increased to 3,145.78 crore fro..."
      }
    ],
    "total": 126,
    "sid": "10039479",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/sai-life-sciences-10039479"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "28-Jan-2026",
      "details": "Earnings Conference Invite to discuss Un-audited Financial Results of the Company for the Third Quarter and Nine Months ended 31 December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "28-Jan-2026",
      "details": "Strategic Collaboration between Mabtech and Sai Life Sciences to advance Immunology Research with EYRA Platform at Sai Boston Site.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consideration And Approval Of Un-Audited Financial Results For The Third Quarter And Nine Months Ended December 31 2025.",
      "datetime": "22-Jan-2026",
      "details": "Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve Un-audited Financial Results for the third quarter and nine months ended December 31 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sai Life's Evaluation Metrics Revised Amidst Positive Financial Trends

2025-11-27 10:06:45

Sai Life, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a revision in its evaluation metrics reflecting shifts in its financial and market performance. This adjustment highlights evolving perspectives on the company’s quality, valuation, financial trends, and technical outlook amid a backdrop of steady operational growth and market activity.

Are Sai Life latest results good or bad?

2025-11-18 19:32:50

Sai Life Sciences has reported its Q2 FY26 results, showcasing notable operational performance. The company achieved a net profit of ₹83.84 crores, reflecting a significant year-on-year increase of 101.98%. Revenue for the quarter reached ₹537.47 crores, marking a 35.88% growth compared to the same period last year, and an 8.27% sequential improvement from the previous quarter. This growth trajectory suggests a recovery in client demand and effective project execution. The operating margin improved to 27.13%, up from 25.84% a year earlier, indicating enhanced operational leverage. The PAT margin also saw an increase, rising to 15.60%, which is a 511 basis point improvement year-on-year. The company’s operating profit, excluding other income, was reported at ₹145.83 crores, reflecting a 42.67% increase from the previous year. Interest expenses have significantly decreased by 55.32% year-on-year to ₹9.35 cr...

How has been the historical performance of Sai Life?

2025-11-17 23:27:40

Answer: The historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Sai Life's consolidated net sales increased from 1,465.18 Cr in March 2024 to 1,694.57 Cr in March 2025, reflecting a strong upward trend in total operating income as well. The company's total expenditure rose to 1,288.91 Cr from 1,179.69 Cr, with notable increases in raw material costs and employee costs. Operating profit (PBDIT) improved significantly, reaching 442.44 Cr, up from 314.58 Cr, while profit before tax also saw a substantial rise to 227.70 Cr from 109.23 Cr. Consequently, profit after tax surged to 170.13 Cr compared to 82.81 Cr the previous year. The operating profit margin increased to 23.94% from 19.48%, and the PAT margin improved to 10.04% from 5.65%. On the balance sheet, total assets grew to 3,145.78 Cr from 2,262.00 Cr, driven by increases in s...

Sai Life Sciences Q2 FY26: Strong Profit Surge Masks Valuation Concerns

2025-11-17 22:47:58

Sai Life Sciences Ltd., a contract research and manufacturing services (CRAMS) provider in the pharmaceutical sector, delivered a robust performance in Q2 FY26 with net profit surging 101.98% year-on-year to ₹83.84 crores, up 38.67% sequentially from ₹60.46 crores in Q1 FY26. The Hyderabad-based company, with a market capitalisation of ₹18,529 crores, demonstrated strong operational momentum as revenue climbed 35.88% YoY to ₹537.47 crores, though the stock's premium valuation at 107 times trailing earnings continues to raise eyebrows among value-conscious investors.

Are Sai Life latest results good or bad?

2025-11-07 19:27:44

Sai Life Sciences' latest financial results for Q2 FY26 present a mixed picture of performance. The company reported a net profit of ₹60.46 crores, reflecting a significant quarter-on-quarter decline of 31.51%. This drop in profitability occurred despite a strong year-on-year revenue growth of 77.47%, with net sales reaching ₹496.42 crores. However, sequentially, revenues fell by 14.34% from the previous quarter, indicating operational challenges that may be impacting the company's ability to maintain profitability alongside its growth trajectory. The operating margin, excluding other income, contracted to 24.36%, down from 27.19% in the prior quarter, suggesting that cost pressures are outpacing revenue growth. The profit after tax margin also saw a decline, from 15.23% to 12.18%, highlighting the need for the company to address these margin pressures effectively. On a positive note, the balance sheet re...

Sai Life Sciences Q2 FY26: Robust Revenue Growth Masks Margin Pressure and Profit Decline

2025-11-07 10:52:14

Sai Life Sciences Ltd., a contract research and manufacturing organisation (CRAM) in the pharmaceutical sector, reported mixed results for Q2 FY26, with net profit declining 31.51% quarter-on-quarter to ₹60.46 crores despite robust revenue growth. The stock reacted sharply, falling 4.30% to ₹882.45 on November 7, 2025, as investors digested the margin compression and sequential profit decline. With a market capitalisation of ₹18,546.61 crores, the small-cap pharma player finds itself navigating a challenging period of operational adjustments despite maintaining strong year-on-year growth momentum.

How has been the historical performance of Sai Life?

2025-11-06 23:07:14

Answer: The historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: In the fiscal year ending March 2025, Sai Life reported net sales of 1,694.57 crore, an increase from 1,465.18 crore in the previous year. Total operating income also rose to 1,694.57 crore, with total expenditure excluding depreciation increasing to 1,288.91 crore from 1,179.69 crore. The operating profit (PBDIT) saw a substantial rise to 442.44 crore, compared to 314.58 crore in March 2024, leading to a profit before tax of 227.70 crore, up from 109.23 crore. Consequently, the profit after tax reached 170.13 crore, nearly doubling from 82.81 crore the previous year. The company's earnings per share (EPS) decreased to 8.16 from 45.88, while the operating profit margin improved to 23.94% from 19.48%. On the balance sheet, total assets increased to 3,145.78 crore fro...

View All News